Charles Schwab Investment Management Inc Sigilon Therapeutics, Inc. Transaction History

Charles Schwab Investment Management Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.74 - $1.64 $23,363 - $51,778	-31,572 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$1.24 - $3.03 $10,123 - $24,736	-8,164 Reduced 20.55%	31,572 $47,000
Q3 2021 Nov 16, 2021	SELL	$4.42 - $10.61 $18,285 - $43,893	-4,137 Reduced 9.43%	39,736 $225,000
Q2 2021 Aug 16, 2021	SELL	$9.15 - $20.17 $51,240 - $112,952	-5,600 Reduced 11.32%	43,873 $471,000
Q1 2021 May 17, 2021	BUY	$18.76 - $40.91 $928,113 - $2.02 Million	49,473 New	49,473 $1.11 Million

Ticker SGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,399,300
Description
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neuro...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.